Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harith Rajagopalan

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Nature|March 6, 2004
Inactivation of hCDC4 can cause chromosomal instabilityHarith Rajagopalan, Prasad V Jallepalli, Carlo Rago, et al.
Cancer Cell|February 1, 2003
Histone modifications and silencing prior to DNA methylation of a tumor suppressor geneKurtis E Bachman, Ben Ho Park, Ina Rhee, et al.
Plos One|March 31, 2021
Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonismJason A West, Anastasia Tsakmaki, Soumitra S Ghosh, et al.
Gastrointestinal Endoscopy|April 3, 2019
Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical settingRehan J Haidry, Annieke C van Baar, Manoel P Galvao Neto, et al.
Diabetes Care|August 14, 2016
Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept StudyHarith Rajagopalan, Alan D Cherrington, Christopher C Thompson, et al.
Gastrointestinal Endoscopy|January 27, 2024
Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot studyCeline B E Busch, Suzanne Meiring, Annieke C G van Baar, et al.
Science (New York, N.Y.)|August 8, 2009
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cellsJihye Yun, Carlo Rago, Ian Cheong, et al.
Diabetes Research and Clinical Practice|January 15, 2022
Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)Annieke C G van Baar, Jacques Devière, David Hopkins, et al.
Gut|February 18, 2021
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trialGeltrude Mingrone, Annieke Cg van Baar, Jacques Devière, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Nature|March 6, 2004
Inactivation of hCDC4 can cause chromosomal instabilityHarith Rajagopalan, Prasad V Jallepalli, Carlo Rago, et al.
Cancer Cell|February 1, 2003
Histone modifications and silencing prior to DNA methylation of a tumor suppressor geneKurtis E Bachman, Ben Ho Park, Ina Rhee, et al.
Plos One|March 31, 2021
Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonismJason A West, Anastasia Tsakmaki, Soumitra S Ghosh, et al.
Gastrointestinal Endoscopy|April 3, 2019
Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical settingRehan J Haidry, Annieke C van Baar, Manoel P Galvao Neto, et al.
Diabetes Care|August 14, 2016
Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept StudyHarith Rajagopalan, Alan D Cherrington, Christopher C Thompson, et al.
Gastrointestinal Endoscopy|January 27, 2024
Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot studyCeline B E Busch, Suzanne Meiring, Annieke C G van Baar, et al.
Science (New York, N.Y.)|August 8, 2009
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cellsJihye Yun, Carlo Rago, Ian Cheong, et al.
Diabetes Research and Clinical Practice|January 15, 2022
Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)Annieke C G van Baar, Jacques Devière, David Hopkins, et al.
Gut|February 18, 2021
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trialGeltrude Mingrone, Annieke Cg van Baar, Jacques Devière, et al.
Pageof 2